Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ash Stevens to Manufacture API for ARIAD Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ash Stevens to Manufacture API for ARIAD Drug

Riverview, MI facility gains FDA approval

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ash Stevens, Inc. (ASI) has received FDA approval of its facility in Riverview, MI to manufacture the API in ARIAD Pharmaceuticals’ drug Iclusig (ponatinib), which was recently approved to treat chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant to prior TKI therapy.
 
“We are very proud to be ARIAD Pharmaceuticals’ outsourcing partner for the development and manufacture of this important API. We have a collaborative and highly productive relationship with ARIAD and we are excited to help provide this innovative therapy to cancer patients,” said Dr. Stephen A. Munk, president and chief executive officer of Ash Stevens, Inc. Ash Stevens to Manufacture API for ARIAD Drug

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics